Brought to you by 
Immuno-oncology firm Tioma Therapeutics closes $86mm Series A round
06 Sep 2016
Executive Summary
Tioma Therapeutics Inc. (developing immunotherapies for solid tumors and blood cancers) raised $86mm through its Series A venture round. RiverVest Venture Partners, Novo Ventures, Roche Venture Fund, and SR One all co-led, and each take seats on the company's board. (Dr. John KcKearn of RiverVest will serve as chairman.)
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Immuno-oncology firm Tioma Therapeutics closes $86mm Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice